APN 201306180039A
Cautionary Announcement

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
("Aspen" or "the Company")

CAUTIONARY ANNOUNCEMENT

Shareholders are advised that Aspen and Aspen Global
Incorporated (“AGI” - a wholly owned subsidiary of Aspen)
are currently engaged in discussions with GlaxoSmithKline
plc (“GSK”) in respect of a possible transaction. Aspen
and AGI have made a combined offer to GSK in terms
whereof:

  •   AGI will acquire from GSK the Arixtra and
      Fraxiparine/Fraxodi brands (“the Brands”) and
      business worldwide, except in China, Pakistan and
      India - these Brands generated approximately £420
      million in revenue for GSK in its 2012 financial
      year ended 31 December 2012. The Brands would
      transfer to AGI at the end of 2013; and

  •   Aspen will   acquire from GSK a specialised sterile
      production   site which manufactures the Brands at
      Notre Dame   de Bondeville, France (“the Site”). The
      Site would   transfer to Aspen during the fourth
      quarter of   Aspen’s 2014 financial year.

(collectively “the Proposed Transaction”).

The conclusion of the Proposed Transaction will be
subject to GSK’s acceptance of the offer, consultation
with affected GSK employees, certain regulatory approvals
and approval by Aspen’s shareholders.

Accordingly shareholders are advised to exercise caution
when dealing in the Company’s securities until a further
announcement in this regard is made.

Durban
18 June 2013



Sponsor
Investec Bank Limited

Date: 18/06/2013 01:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.